Shattuck Labs(US:STTK) Globenewswire·2025-11-06 21:30Core Viewpoint - Shattuck Labs, Inc. has initiated a Phase 1 clinical trial for its lead product candidate SL-325, a DR3 blocking antibody, and has reported financial results for Q3 2025, highlighting its strong capital position to advance clinical development [1][2][3]. Business Highlights - SL-325 is the first DR3 blocking antibody to enter clinical development, with the Phase 1 trial proceeding as planned [2]. - The company closed a private placement of approximately $103 million in August 2025, which is expected to fund operations into 2029 and support multiple clinical milestones for SL-325 [3][6]. - Recent appointments to the Board of Directors include Dan Baker, M.D., and Mona Ashiya, Ph.D., enhancing the company's leadership [4][6]. Clinical Development - The Phase 1 trial for SL-325 began with the first participants dosed in Q3 2025, focusing on safety, tolerability, immunogenicity, and pharmacokinetics [7]. - Enrollment for the single-ascending dose (SAD) and multiple-ascending dose (MAD) portions is expected to be completed by Q2 2026, with initial results anticipated by the same timeframe [7]. - The company is also developing preclinical DR3-based bispecific antibodies aimed at treating inflammatory bowel disease (IBD) [7]. Financial Results - As of September 30, 2025, cash and cash equivalents were approximately $86.1 million, down from $90.1 million a year earlier [10][14]. - Research and Development (R&D) expenses for Q3 2025 were $7.6 million, a decrease from $16.3 million in Q3 2024 [14]. - The net loss for Q3 2025 was $10.1 million, or $0.14 per share, compared to a net loss of $16.6 million, or $0.33 per share, in the same quarter of the previous year [14][21].